All Drug Development articles – Page 10
-
ArticleWhen chemistry corrects biology: the deuterated return of a MET inhibitor
A promising MET inhibitor failed in the clinic due to human-specific metabolism. Now its deuterated analogue, DO-2, is showing that a simple isotope swap might overcome the problem.
-
NewsNew antibiotic discovery could help tackle antimicrobial resistance
Scientists have discovered a powerful new antibiotic hidden within the compound pre-methylenomycin C lactone, which shows real effectiveness against drug-resistant infections such as MRSA and VRE.
-
NewsTRF1 protein identified as potential obesity drug target
Researchers have discovered that removing a telomere-protecting protein, TRF1, makes mice leaner and metabolically healthier without shortening their telomeres, potentially leading to new methods for tackling obesity and age-related diseases.
-
NewsNew PET tracer could lead to better ALS and Alzheimer’s diagnosis
New preclinical data on ACI-19626, a first-in-class PET tracer for imaging TDP-43 pathology, shows potential to greatly improve early diagnosis and treatment of multiple neurodegenerative diseases.
-
ArticleFrom war rooms to launch rooms: how AI is changing the game
Within3’s Jason Smith explores how artificial intelligence is breathing new life into next-generation launch situation rooms; delivering actionable insights for pharmaceutical companies.
-
ArticleThe predictive validity crisis: Pharma’s productivity paradox – Part II
Part II shows that the predictive validity crisis can be solved by rethinking how the industry chooses models, measures outcomes and integrates systems. Success stories from Vertex, Regeneron and AstraZeneca illustrate how aligning biology, measurement and strategy can reverse decades of declining productivity.
-
NewsNew compound blend reverses sugar damage to tackle ageing and obesity
Scientists have developed a compound blend that reverses sugar-related cellular damage in mice, which could lead to future therapies to slow ageing and treat metabolic diseases.
-
NewsPulmonary fibrosis: new drug slows and reverses lung scarring
Researchers have identified a key cellular mechanism that drives pulmonary fibrosis and successfully blocked it in mice, reducing lung scarring.
-
ArticleHow real-world data is accelerating drug discovery
Vish Srivastava considers the benefits of expanding the role of real-world data in drug discovery to provide improved therapies, faster and with greater success.
-
NewsStem cell liver model reproduces rare immune drug reactions
A new human liver organoid platform could help predict which drugs trigger dangerous immune reactions in susceptible patients.
-
NewsImproving brain resilience: Rab proteins and future treatments
New research has discovered how Rab proteins control the delivery of critical supplies to strengthen neural connections, providing researchers with important insights into memory formation and potential strategies for Alzheimer’s resilience.
-
NewsMeta-Flux expands AI platform to speed up drug development
Dublin-based biotech Meta-Flux has raised €1.8M ($2M) in seed funding to expand its AI-driven platform for preclinical drug development, helping researchers predict drug success and accelerate the pathway from lab to clinic.
-
NewsHow nanocarriers and VLPs are uniting to fight cancer
Innovations in nanomedicine are merging to redefine precision oncology. From virus-like particles to magnetic nanoparticles, integrated delivery systems are showing powerful potential for new, targeted cancer treatments.
-
NewsSperm ‘switch’ discovery could lead to new fertility therapies
Scientists have discovered the molecular ‘switch’ that powers sperm for fertilisation, which could potentially lead to new infertility treatments.
-
NewsNew gene therapy restores brain function in SYNGAP1 disorder
Scientists have developed a new gene therapy that reversed symptoms of SYNGAP1-related brain disorders in mice, which could lead to new treatments for this group of neurological conditions.
-
ArticleEye movements as objective biomarkers: accelerating CNS drug development
Measuring disease progression remains one of the biggest hurdles in CNS drug development. Eye movements, now trackable with just a laptop and webcam, are emerging as a sensitive and scalable biomarker that could transform how trials are designed and therapies reach patients.
-
NewsNew UCLA drug could restore heart and organ function
UCLA researchers have developed a monoclonal antibody, AD-NP1, that blocks ENPP1 to enhance heart repair and reduce scar tissue.
-
NewsDDHD2 enables neurons to synthesise and burn fat for energy
Scientists have discovered that neurons can burn and make their own fats for energy – a finding that could lead to new treatments for rare and currently untreatable brain diseases.
-
ArticleAdvancing gene editing: the role of lipid nanoparticles in CRISPR delivery
CRISPR therapies depend on delivery and lipid nanoparticles are emerging as a more flexible and scalable option than viral vectors.
-
NewsPemafibrate and telmisartan combo may reverse fatty liver
A new study shows that approved drugs, pemafibrate and telmisartan, when combined, can reduce liver fat and may lower cardiovascular risk in metabolic dysfunction-associated steatotic liver disease.